# US 2003/0225098 A1 · Kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225098 A1
- Document ID: US20030225098A1
- Status: Published application
- Kind: A1
- Application number: 10/394,965
- Filed: 2003-03-21
- Published: 2003-12-04
- Earliest claimed: 2002-03-21
- Inventors: Gavin C. Hirst; Lee D. Arnold; Andrew Burchat; Neil Wishart; David Calderwood; Carol K. Wada; Michael R. Michaelides; Zhiqin Ji; Melanie Muckey
- Web page: https://patentgrep.com/patent/US20030225098A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 491/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application is directed to pyrazolopyrirnidine and furopyrimidine analogs of the formula (I) 1 wherein the substituents are as defined herein, which are useful as kinase inhibitors.

## Claims

### Claim 1

A compound of the formula I,
44
the racemic-diastereomeric mixtures, optical isomers, pharmaceutically-acceptable salts, prodrugs or biologically active metabolites thereof, wherein
the dotted line in the structure of formula (I) represents an optional double bond;
X is CR1 or NR; Y is O, CRq or N; Q is N, NR2or O;
R3 for each occurrence is independently hydrogen, hydroxy, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy;
when X is CR1, Y is CRq, Q is O and there is a double bond between X and Y; or when X is CR1, Y is N, Q is O and there is a double bond between X and Y; or when X is CR1, Y is O, Q is N and there is a double bond between Q and the pyrimidinyl ring, then
45
where Z100 is nitro, optionally substituted amino,
46
or a group optionally substituted with Rb selected from the group consisting of cycloalkyl, naphthyl, tetrahydronaphthyl, benzothienyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl,
47
thiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl, isoxazolyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, indolinyl, indazolyl, benzoisothiazolyl, pyrido-oxazolyl, pyrido-thiazolyl, pyrimido-oxazolyl, pyrimido-thiazolyl and benzimidazolyl;
when a is 1 and D1, G1, J1, L1 and M1 are each independently selected from the group consisting of CRa and N, provided that at least two of D1, G1, J1, L1 and M1 are CRa; or
when a is 0, and one of D1, G1, L1 and M1 is NRa, one of D1, G1, L1 and M1 is CRa and the remainder are independently selected from the group consisting of CRa and N;
when b is 1 and D2, G2, J2, L2 and M2 are each independently selected from the group consisting of CRa and N, provided that at least two of D2, G2, J2, L2 and M2 are CRa; or
when b is 0, and one of D2, G2, L2 and M2 is NRa, one of D2, G2, L2 and M2 is CRa and the remainder are independently selected from the group consisting of CRa and N;
Ra and Rb each represent one or more substituents and are for each occurrence independently selected from the group consisting of hydrogen, halogen, —CN, —NO2, —C(O)OH, —C(O)H, —OH, —C(O)O-alkyl, —Z105—C(O)N(R)2, —Z105—N(R)—C(O)—Z200, —Z105—N(R)—S(O)2—Z200, Z105—N(R)—C(O)—N(R)—Z200, Rc, CH2ORc, tetrazolyl, trifluoromethylcarbonylamino, trifluoromethylsulfonamido, and an optionally substituted group selected from the group consisting of carboxamido, alkyl, alkoxy, aryl, alkenyl, aryloxy, heteroaryloxy, arylalkyl, alkynyl, amino, aminoalkyl, amido groups, heteroarylthio and arylthio;
Z105 for each occurrence is independently a covalent bond or (C1-C6);
Z200 for each occurrence is independently an optionally substituted (C1-C6), optionally substituted phenyl, or optionally substituted —(C1-C6)-phenyl;
Rc for each occurrence is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, —CH2—NRdRe, —W—(CH2)t—NRdRe, —W—(CH2)t-Oalkyl, —W—(CH2)t—S-alkyl or —W—(CH2)t—OH;
Rd and Re for each occurrence are independently H, alkyl, alkanoyl or SO2-alkyl; or Rd, Re and the nitrogen atom to which they are attached together form a five- or six-membered heterocyclic ring;
t for each occurrence is independently an integer from 2 to 6;
W for each occurrence is independently a direct bond or O, S, S(O), S(O)2, or NRf;
Rf for each occurrence is independently H or alkyl;
Z110 is a covalent bond, or an optionally substituted (C1-C6) which is optionally substituted with one or more substituents selected from the group consisting of alkyl, CN, OH, halogen, NO2, COOH, optionally substituted amino and optionally substituted phenyl;
Z111 is a covalent bond, an optionally substituted (C1-C6) or an optionally substituted —(CH2)n-cycloalkyl-(CH2)n—; where the optionally substituted groups are optionally substituted with one or more substituents selected from the group consisting of alkyl, CN, OH, halogen, NO2, COOH, optionally substituted amino and optionally substituted phenyl;
or R1 is a substituted or unsubstituted carbocyclic or heterocyclic ring fused with ring 2;
A is a covalent bond, —O—; —S—; —S(O)p—; —N(R)—; —N(C(O)OR)—; —N(C(O)R)—; —N(SO2R)—; —CH2O—; —CH2S—; —CH2N(R)—; —CH(NR)—; —CH2N(C(O)R))—; —CH2N(C(O)OR)—; —CH2N(SO2R)—; —CH(NHR)—; —CH(NHC(O)R)—; —CH(NHSO2R)—; —CH(NHC(O)OR)—; —CH(OC(O)R)—; —CH(OC(O)NHR); —CH═CH—; —C(═NOR)—; —C(O)—; —CH(OR)—; —C(O)N(R)—; —N(R)C(O)—; —N(R)S(O)p—; —OC(O)N(R)—; ; —N(R)—C(O)—(CH2)n—N(R)—, —N(R)C(O)O—; —N(R)—(CH2)n+1—C(O)—, —S(O)pN(R)—; —O—(CR2)n+1—C(O)—, —O—(CR2)n+1—O—, —N(C(O)R)S(O)p—; —N(R)S(O)pN(R)—; —N(R)—C(O)—(CH2)n—O—, —C(O)N(R)C(O)—; —S(O)pN(R)C(O)—; —OS(O)pN(R)—; —N(R)S(O)pO—; —N(R)S(O)pC(O)—; —SOpN(C(O)R)—; —N(R)SOpN(R)—; —C(O)O—; —N(R)P(ORg)O—; —N(R)P(ORg)—; —N(R)P(O)(ORg)O—; —N(R)P(O)(ORg)—; —N(C(O)R)P(ORg)O—; —N(C(O)R)P(ORg)—; —N(C(O)R)P(O)(ORg)O—, or —N(C(O)R)P(ORg)—;
p is 1 or 2;
R for each occurrence is independently H, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted aryl;
Rg for each occurrence is independently H, or an optionally substituted group selected from the group consisting of alkyl, arylalkyl, cycloalkyl and aryl;
or R, Rg, the nitrogen atom and the phosphorus atom, together form a five- or six-membered heterocyclic ring when R and Rg are in a phosphorus containing group; or
A is NRSO2 and R, Ra and the nitrogen atom together form an optionally substituted five or six-membered heterocyclic ring fused to ring 1;
n for each occurrence is independently an integer from 0 to 6;
Rq is selected from the group consisting of hydrogen, alkoxyalkyl, alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heteroaralkyl, optionally substituted (heterocycloalkyl)alkyl, and halo; wherein the arylalkyl, the cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the (heterocycloalkyl)alkyl are each optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkyl, hydroxy, hydroxyalkyl and nitro; or
when X is NR1 and R3 are each H, then Y is N, Q is CR2, there is a double bond between Y and Q, and
48
wherein Ra is H or —OMe;
A is —NH—CO—, —NH—SO2—, —NH—C(O)O— or —NH—C(O)—NH—;
B is N-methyl-indol-2-yl, (fluoro)(trifluoromethyl)phenyl, phenyl or benzyl;
R2 is H, 4-piperidinyl,
49
N-ethylpiperidin-4-yl or
50
when X is CR1 and one of R3 is not H, then Y is N, Q is NR2, there is a double bond between X and Y, and
51
where Z100 is nitro, optionally substituted amino,
52
or a group optionally substituted with Rb selected from the group consisting of cycloalkyl, naphthyl, tetrahydronaphthyl, benzothienyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl,
53
thiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl, isoxazolyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, indolinyl, indazolyl, benzoisothiazolyl, pyrido-oxazolyl, pyrido-thiazolyl, pyrimido-oxazolyl, pyrimido-thiazolyl and benzimidazolyl;
when a is 1 and D1, G1, J1, L1 and M1 are each independently selected from the group consisting of CRa and N, provided that at least two of D1, G1, J1, L1 and M1 are CRa; or
when a is 0, and one of D1, G1, L1 and M1 is NRa, one of D1, G1, L1 and M1 is CRa and the remainder are independently selected from the group consisting of CRa and N;
when b is 1 and D2, G2, J2, L2 and M2 are each independently selected from the group consisting of CRa and N, provided that at least two of D2, G2, J2, L2 and M2 are CRa; or
when b is 0, and one of D2, G2, L2 and M2 is NRa, one of D2, G2, L2 and M2 is CRa and the remainder are independently selected from the group consisting of CRa and N;
Ra and Rb each represent one or more substituents and are for each occurrence independently selected from the group consisting of hydrogen, halogen, —CN, —NO2, —C(O)OH, —C(O)H, —OH, —C(O)O-alkyl, —Z105—C(O)N(R)2, —Z105—N(R)—C(O)—Z200, —Z105—N(R)—S(O)2—Z200, —Z105—N(R)—C(O)—N(R)—Z200, Rc, CH2ORc, tetrazolyl, trifluoromethylcarbonylamino, trifluoromethylsulfonamido, and an optionally substituted group selected from the group consisting of carboxamido, alkyl, alkoxy, aryl, alkenyl, aryloxy, heteroaryloxy, arylalkyl, alkynyl, amino, aminoalkyl, amido groups, heteroarylthio and arylthio;
Z105 for each occurrence is independently a covalent bond or (C1-C6);
Z200 for each occurrence is independently an optionally substituted (C1-C6), optionally substituted phenyl, or optionally substituted —(C1-C6)-phenyl;
Rc for each occurrence is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, —CH2—NRdRe, —W—(CH2)t—NRdRe, —W—(CH2)t-Oalkyl, —W—(CH2)t—S-alkyl or —W—(CH2)t—OH;
Rd and Re for each occurrence are independently H, alkyl, alkanoyl or SO2-alkyl; or Rd, Re and the nitrogen atom to which they are attached together form a five- or six-membered heterocyclic ring;
t for each occurrence is independently an integer from 2 to 6;
W for each occurrence is independently a direct bond or O, S, S(O), S(O)2, or NRf;
Rf for each occurrence is independently H or alkyl;
Z110 is a covalent bond, or an optionally substituted (C1-C6) which is optionally substituted with one or more substituents selected from the group consisting of alkyl, CN, OH, halogen, NO2, COOH, optionally substituted amino and optionally substituted phenyl;
Z111 is a covalent bond, an optionally substituted (C1-C6) or an optionally substituted —(CH2)n-cycloalkyl—(CH2)n—; where the optionally substituted groups are optionally substituted with one or more substituents selected from the group consisting of alkyl, CN, OH, halogen, NO2, COOH, optionally substituted amino and optionally substituted phenyl;
or R1 is a substituted or unsubstituted carbocyclic or heterocyclic ring fused with ring 2;
A is a covalent bond, —O—; —S—; —S(O)p—; —N(R)—; —N(C(O)OR)—; —N(C(O)R)—; —N(SO2R)—; —CH2O—; —CH2S—; —CH2N(R)—; —CH(NR)—; —CH2N(C(O)R))—; —CH2N(C(O)OR)—; —CH2N(SO2R)—; —CH(NHR)—; —CH(NHC(O)R)—; —CH(NHSO2R)—; —CH(NHC(O)OR)—; —CH(OC(O)R)—; —CH(OC(O)NHR); —CH═CH—; —C(═NOR)—; —C(O)—; —CH(OR)—; —C(O)N(R)—; —N(R)C(O)—; —N(R)S(O)p—; —OC(O)N(R)—; ; —N(R)—C(O)—(CH2)n—N(R)—, —N(R)C(O)O—; —N(R)—(CH2)n+1—C(O)—, —S(O),N(R)—; —O—(CR2)n+1—C(O)—, —O—(CR2)n+1—O—, —N(C(O)R)S(O)p—; —N(R)S(O)pN(R)—; —N(R)—C(O)—(CH2)nO—, —C(O)N(R)C(O)—; —S(O)pN(R)C(O)—; —OS(O)pN(R)—; —N(R)S(O)pO—; —N(R)S(O)pC(O)—; —SOpN(C(O)R)—; —N(R)SOpN(R)—; —C(O)O—; —N(R)P(ORg)O—; —N(R)P(ORg)—; —N(R)P(O)(ORg)O—; —N(R)P(O)(ORg)—; —N(C(O)R)P(ORg)O—; —N(C(O)R)P(ORg)—; —N(C(O)R)P(O)(ORg)O—, or —N(C(O)R)P(ORg)—;
p is 1 or2;
R for each occurrence is independently H, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted aryl;
Rg for each occurrence is independently H, or an optionally substituted group selected from the group consisting of alkyl, arylalkyl, cycloalkyl and aryl;
or R, Rg, the nitrogen atom and the phosphorus atom, together form a five- or six-membered heterocyclic ring when R and Rg are in a phosphorus containing group; or
A is NRSO2 and R, Ra and the nitrogen atom together form an optionally substituted five or-six-membered heterocyclic ring fused to ring 1;
R2 is —Z101—Z102;
Z101 is a covalent bond, —(C1-C6)—, —(C1-C6)—O—, —(C1-C6)—C(O)—, —(C1-C6)—C(O)O—, —(C1-C6)—C(O)—NH—, —(C1-C6)—C(O)—N((C1-C6))— or an optionally substituted phenyl group;
Z102 is hydrogen, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted saturated or unsaturated heterocyclic group, or an optionally substituted saturated or unsaturated heterobicyclic group;
said substituted heterocyclic or substituted heterobicyclic group having one or more substituents each independently selected from the group consisting of hydroxyl, cyano, optionally substituted alkoxy, optionally substituted sulfonamido, optionally substituted ureido, optionally substituted carboxamido; optionally substituted amino, oxo, a saturated or unsaturated or aromatic optionally substituted heterocyclic group;
wherein the heterocyclic group comprises one or more nitrogen atoms, one or more oxygen atoms or a combination thereof and where said nitrogen atoms are independently optionally substituted by a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted arylalkyl; or
R2 is of the formula B-E;
B is hydroxy or an optionally substituted group selected from the group consisting of cycloalkyl, azacycloalkyl, amino, aminoalkylsulfonyl, alkoxyalkyl, alkoxy, aminoalklylcarbonyl, alkylenyl, aminoalkyl, alkylenylcarbonyl and aminoalkylcarbonyl;
E is an optionally substituted group selected from the group consisting of azacycloalkyl, azacycloalkylcarbonyl, azacycloalkylsulfonyl, azacycloalkylalkyl, heteroaryl, heteroarylcarbonyl, heteroarylsulfonyl, heteroarylalkyl, azacycloalkylcarbonylamino, heteroarylcarbonylamino and aryl; and
n for each occurrence is independently an integer from 0 to 6.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein X is CR1, Y is CRq, Q is O and there is a double bond between X and Y; or X is CR1, Y is N, Q is O and there is a double bond between X and Y; or X is CR1, Y is O, Q is N and there is a double bond between Q and the pyrimidinyl ring.

### Claim 3 (depends on 2)

A compound according to claim 2 of formula (II),
54
wherein
Rq is selected from the group consisting of hydrogen, alkoxyalkyl, alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heteroaralkyl, optionally substituted (heterocycloalkyl)alkyl, and halo, wherein the arylalkyl, the cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the (heterocycloalkyl)alkyl are each optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkyl, hydroxy, hydroxyalkyl, and nitro;
A is selected from the group consisting of —N(R)—C(O)—(CH2)n—N(R)—, —N(R)—, —N(R)C(O)—, and —N(R)S(O)p—;
Z100 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
n is 0; p is 2; and R is hydrogen.

### Claim 4 (depends on 3)

The compound of claim 3 wherein R is hydrogen.

### Claim 5 (depends on 4)

The compound of claim 4 selected from the group consisting of
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(4-methylphenyl)urea;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-methylphenyl)urea;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(2-methylphenyl)urea;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-chlorophenyl)urea;
5-[4-(1,3-benzoxazol-2-ylamino)phenyl]furo[2,3-d]pyrimidin-4-amine;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzamide; and
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide.

### Claim 6 (depends on 3)

The compound of claim 3 wherein Rq is selected from the group consisting of alkyl and halo.

### Claim 7 (depends on 6)

The compound of claim 6 selected from the group consisting of
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(2-methylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(4-methylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzanide;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-methylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-chlorophenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-methoxyphenyl)urea;
N-[4-(4-amino-6-bromofuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-methylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-bromophenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-ethylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyriridin-5-yl)phenyl]-N′-(3,5-dimethylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3,5-dichlorophenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea;
1-[4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(4-cyano-phenyl)-urea; and
1-[4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea.

### Claim 8 (depends on 2)

A compound according to claim 2 of formula (III),
55
wherein
A is selected from the group consisting of a bond, —N(R)C(O)—, and —N(R)—C(O)—(CH2)n—N(R)—;
Z100 is selected from the group consisting of —NO2, amino, substituted amino, and optionally substituted aryl;
R is hydrogen; and n is 0.

### Claim 9 (depends on 8)

The compound of claim 8 wherein
A is a bond; and Z100 is selected from the group consisting of —NO2, substituted amino, and amino.

### Claim 10 (depends on 9)

The compound of claim 9 selected from the group consisting of
3-(4-nitrophenyl)isoxazolo[5,4-d]pyrimidin-4-amine; and
3-(4-aminophenyl)isoxazolo[5,4-d]pyrimidin-4-amine.

### Claim 11 (depends on 8)

The compound of claim 8 wherein
A is selected from the group consisting of —N(R)C(O)—, and —N(R)—C(O)—(CH2)n—N(R)—; and Z100 is optionally substituted aryl.

### Claim 12 (depends on 11)

The compound of claim 11 selected from the group consisting of
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N′-(3-methylphenyl)urea;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N′-(3-ethylphenyl)urea;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N′-(3-chlorophenyl)urea;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]benzamide;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N′-[3-(trifluoromethyl)phenyl]urea; and
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea.

### Claim 13 (depends on 1)

A compound according to claim 1, wherein X is NR1; both R3 are each H; Y is N; Q is CR2; and there is a double bond between Y and Q.

### Claim 14 (depends on 13)

A compound according to claim 13, wherein the compound or the pharmaceutically acceptable salt thereof is
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide;
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-2-fluoro-4-(trifluoromethyl)benzamide;
N1-[4-(7-Amino-1H-pyrazolo[4,3-d]pyrimidin-1-yl)-2-Methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide;
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-benzenesulfonamide;
Benzyl N-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}carbamate;
N-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-N-phenylurea;
N2-{4-[7-Amino-3-(1-tetrahydro-2H-4-pyranyl-4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide;
N2-{4-[7-amino-3-(1-ethyl-4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide;
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phenyl}-1-benzenesulfonamide;
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phenyl}-1-methyl-1H-2-indolecarboxamide; or
N2-{4-[7-Amino-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide.

### Claim 15 (depends on 1)

A compound according to claim 1, wherein X is CR1; one of R3 is not H; Y is N, Q is NR2; and there is a double bond between X and Y.

### Claim 16 (depends on 1)

A method of inhibiting one or more protein kinase activity in a patient comprising administering a therapeutically effective amount of a compound of claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolites thereof to said patient.

### Claim 17 (depends on 16)

The method of claim 16 wherein said protein kinase is selected from the group consisting of KDR, FGFR-1, PDGFRβ, PDGFRα, IGF-IR, c-Met, Flt-1, Flt-4, TIE-2, TIE-1, Lck, Src, fyn, Lyn, Blk, hck, fgr and yes.

### Claim 18 (depends on 1)

A method of affecting hyperproliferative disorders in a patient comprising administering a therapeutically effective amount of a compound of claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolites thereof to said patient.

### Claim 19 (depends on 1)

A method of affecting angiogenesis in a patient comprising administering a therapeutically effective amount of a compound of claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolites thereof to said patient.

### Claim 20 (depends on 16)

The method of claim 16 wherein the protein kinase is a protein serine/threonine kinase or a protein tyrosine kinase.

### Claim 21 (depends on 1)

A method of treating one or more ulcers in a patient comprising administering a therapeutically effective amount of a compound of claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolites thereof to said patient.

### Claim 22 (depends on 21)

The method of claim 21 wherein the ulcer or ulcers are caused by a bacterial or fungal infection; or the ulcer or ulcers are Mooren ulcers; or the ulcer or ulcers are a symptom of ulcerative colitis.

### Claim 23 (depends on 1)

A method of treating a condition in a patient comprising administering a therapeutically effective amount of a compound of claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolites thereof to said patient, wherein said condition is an ocular condition, a cardiovascular condition, a cancer, Crow-Fukase (POEMS) syndrome, a diabetic condition, sickle cell anaemia, chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, glomerulonephritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, graft rejection, Lyme disease, sepsis, von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, polycystic kidney disease, fibrosis, sarcoidosis, cirrhosis, thyroiditis, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic occlusive pulmonary disease, asthma or edema following burns, trauma, radiation, stroke, hypoxia, ischemia, ovarian hyperstimulation syndrome, preeclampsia, menometrorrhagia, endometriosis, pulmonary hypertension, infantile hemangioma, or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa or toxoplasmosis.

### Claim 24 (depends on 23)

The method of claim 23 wherein the ocular condition is ocular or macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser treatment complications, conjunctivitis, Stargardt's disease, Eales disease, retinopathy or macular degeneration.

### Claim 25 (depends on 23)

The method of claim 23 wherein the cardiovascular condition is atherosclerosis, restenosis, ischemia/reperfusion injury, vascular occlusion or carotid obstructive disease.

### Claim 26 (depends on 23)

The method of claim 23 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, leukemia or malignant ascites.

### Claim 27 (depends on 23)

The method of claim 23 wherein the diabetic condition is insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy or microangiopathy.

### Claim 28 (depends on 1)

A method of decreasing fertility in a patient, said method comprising the step of administering to the patient an effective amount of a compound of claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolite thereof.

### Claim 29 (depends on 19)

The method of claim 19 wherein the compound or a physiologically acceptable salt, prodrug or biologically active metabolite thereof is administered in an amount effective to promote angiogenesis or vasculogenesis.

### Claim 30 (depends on 17)

The method of claim 17 wherein the protein kinase is TIE-2.

### Claim 31 (depends on 29)

The method of claim 29 wherein the compound of formula (I), or physiologically acceptable salt, prodrug or biologically active metabolite thereof, is administered in combination with a pro-angiogenic growth factor.

### Claim 32 (depends on 31)

The method of claim 31 wherein the pro-angiogenic growth factor is selected from the group consisiting of VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-E, HGF, FGF-1, FGF-2, derivatives thereof and antiiodotypic antibodies.

### Claim 33 (depends on 29)

The method of claim 29 wherein the patient is suffering from anemia, ischemia, infarct, transplant rejection, a wound, gangrene or necrosis.

### Claim 34 (depends on 16)

The method of claim 16 wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, the potentiation of an inflammatory response or a combination thereof.

### Claim 35 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
